— Know what they know.
Not Investment Advice
Also trades as: 0K16.L (LSE) · $vol 0M

EOLS NASDAQ

Evolus, Inc.
1W: -2.0% 1M: +24.3% 3M: +47.6% YTD: -4.0% 1Y: -35.2% 3Y: -33.6% 5Y: -28.8%
$6.09
-0.36 (-5.58%)
 
Weekly Expected Move ±9.3%
$5 $6 $6 $7 $8
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Buy · Power 63 · $401.1M mcap · 50M float · 2.26% daily turnover · Short 28% of daily vol

Cash Flow Trends

Operating Cash Flow
-$42M -134.8% ▼
Capital Expenditures
$3M -133.8% ▼
5Y CAGR: +1.9%
Free Cash Flow
-$46M -134.7% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$33M -237.4% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$47M-$74M-$62M-$50M-$52M
Depreciation & Amort.$6M$4M$6M$6M$9M
Stock-Based Comp.$10M$11M$16M$22M$21M
Change in Working Capital-$12M-$34M-$6M-$7M-$22M
Other Non-Cash Items$9M$8M$11M$11M$2M
Operating Cash Flow-$33M-$85M-$34M-$18M-$42M
— Investing Activities —
Capital Expenditures-$393K-$2M-$473K-$1M$0
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$5M$0$0$0$0
Other Investing-$577K-$1M-$1M-$3M-$8M
Investing Cash Flow$4M-$3M-$2M-$5M-$8M
— Financing Activities —
Net Debt Issuance-$24M$0$50M$0-$15K
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing-$6M-$4M-$5M-$4M$16M
Financing Cash Flow$73M-$4M$45M$47M$17M
Net Change in Cash$44M-$92M$9M$24M-$33M
Cash End of Period$146M$54M$63M$87M$54M
Free Cash Flow-$34M-$88M-$36M-$19M-$46M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms